Showing results (71-80 of 132) with videos related to
Sort By:
Pageof 14
Journal of Pharmaceutical and Biomedical Analysis|December 13, 2006
Development and validation of RP-HPLC-UV method for simultaneous determination of buparvaquone, atenolol, propranolol, quinidine and verapamil: a tool for the standardization of rat in situ intestinal permeability studiesGantala Venkatesh, S Ramanathan, S M Mansor, et al.Microorganisms|June 5, 2020
Novel 2D and 3D Assays to Determine the Activity of Anti-Leishmanial DrugsAlec O'Keeffe, Christine Hale, James A Cotton, et al.Pharmaceutics|April 30, 2021
Film-Forming Systems for the Delivery of DNDI-0690 to Treat Cutaneous LeishmaniasisKatrien Van Bocxlaer, Kerri-Nicola McArthur, Andy Harris, et al.European Journal of Medicinal Chemistry|December 4, 2003
Synthesis and in vitro anti-protozoal activity of a series of benzotropolone derivatives incorporating endocyclic hydrazinesHongyu Ren, Shannon Grady, Matthew Banghart, et al.Phytotherapy Research : PTR|August 31, 2002
In vitro activity of Triclisia patens and some bisbenzylisoquinoline alkaloids against Leishmania donovani and Trypanosoma brucei bruceiMaria del Rayo Camacho, J David Phillipson, Simon L Croft, et al.Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|July 4, 2006
Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical useF Javier Pérez-Victoria, María P Sánchez-Cañete, Karin Seifert, et al.Journal of Medicinal Chemistry|December 13, 2005
Antitrypanosomal, antileishmanial, and antimalarial activities of quaternary arylalkylammonium 2-amino-4-chlorophenyl phenyl sulfides, a new class of trypanothione reductase inhibitor, and of N-acyl derivatives of 2-amino-4-chlorophenyl phenyl sulfideSeheli Parveen, Mohammed O F Khan, Susan E Austin, et al.Biomedical Chromatography : BMC|January 22, 2008
Optimization and validation of RP-HPLC-UV method with solid-phase extraction for determination of buparvaquone in human and rabbit plasma: application to pharmacokinetic studyGantala Venkatesh, M I A Majid, S Ramanathan, et al.International Journal of Antimicrobial Agents|July 14, 2007
Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivoKarin Seifert, F Javier Pérez-Victoria, Marianne Stettler, et al.Antimicrobial Agents and Chemotherapy|November 26, 2003
Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin BMalika Larabi, Vanessa Yardley, Philippe M Loiseau, et al.Pageof 14